Home›Trial›NCT03997383

🔬NCT03997383Phase 3ACTIVE NOT RECRUITING

APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)

Study Summary

The purpose of this study is to evaluate the efficacy and safety of patisiran in participants with ATTR amyloidosis with cardiomyopathy.

Conditions

Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

Interventions / Drugs

Placebo Patisiran

View on ClinicalTrials.gov ↗

Sponsor

Alnylam Pharmaceuticals

RNAi Therapeutics

Study Details

Enrollment360 participants

Primary Completion—

Lead SponsorAlnylam Pharmaceuticals

Data Retrieved2026-04-11 02:53:26.219351+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.